161.38MMarket Cap-5058P/E (TTM)
2.630High2.300Low405.24KVolume2.310Open2.310Pre Close1.01MTurnover1.07%Turnover RatioLossP/E (Static)62.55MShares2.63052wk High4.84P/B97.75MFloat Cap1.05052wk Low--Dividend TTM37.89MShs Float22.137Historical High--Div YieldTTM14.29%Amplitude0.607Historical Low2.497Avg Price1Lot Size
Corvus Pharmaceuticals Stock Forum
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024
Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefin...
NEWS
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
NEWS
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
No comment yet